Title:
MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/105878
Kind Code:
A1
Abstract:
The present invention provides isolated antibodies that bind to the human EGFR protein, and ADCs of the antibodies. Pharmaceutical compositions including the antibodies and ADCs, and methods of treating cancer are also provided.
Inventors:
XIA BING (CN)
ZHOU YUHONG (CN)
WEI ZIPING (CN)
CAO LIXIA (CN)
JIANG FANGDUN (CN)
ZHOU YUHONG (CN)
WEI ZIPING (CN)
CAO LIXIA (CN)
JIANG FANGDUN (CN)
Application Number:
PCT/CN2021/131780
Publication Date:
May 27, 2022
Filing Date:
November 19, 2021
Export Citation:
Assignee:
BLISS BIOPHARMACEUTICAL HANGZHOU CO LTD (CN)
International Classes:
C07K16/28; A61K39/395; A61K47/68; A61P35/00; C07K16/30; C12N15/13; C12N15/63
Domestic Patent References:
| WO2017051254A1 | 2017-03-30 |
Foreign References:
| CN103619881A | 2014-03-05 | |||
| CN111939267A | 2020-11-17 | |||
| CN102971342A | 2013-03-13 | |||
| CN103764170A | 2014-04-30 | |||
| CN108025084A | 2018-05-11 |
Other References:
SICKMIER E. ALLEN, KURZEJA ROBERT J. M., MICHELSEN KLAUS, VAZIR MUKTA, YANG EVELYN, TASKER ANDREW S.: "The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance", PLOS ONE, vol. 11, no. 9, 22 September 2016 (2016-09-22), pages e0163366, XP055932026, DOI: 10.1371/journal.pone.0163366
Attorney, Agent or Firm:
SHANGHAI BESHINING LAW OFFICE (CN)
Download PDF: